MyPlate National Strategic Partners Come Together to Launch New Resource to Help Americans Build a Better Sandwich perishablenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from perishablenews.com Daily Mail and Mail on Sunday newspapers.
'Food Pyramid' in Lucky Charm vs Steak discussion was scrapped in 2011 hitc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hitc.com Daily Mail and Mail on Sunday newspapers.
Kindred Biosciences Announces First Quarter 2021 Financial Results
News provided by
Share this article
Share this article
SAN FRANCISCO, May 11, 2021 /PRNewswire/ Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2021 and provided updates on its programs. For the first quarter 2021, KindredBio reported net revenues of $2.4 million and a net loss of $9.7 million, or $0.24 per share. We had a strong start to the year, announcing positive results in a new long-acting interleukin-31 antibody program that has the potential to become a best-in-class therapeutic, alongside the acceptance of efficacy data for our parvovirus monoclonal antibody program. With cash runway now through the end of 2023, we are well-positioned to realize the value of our promising late-stage pipeline, said KindredBio s Chief Executive Officer, Richard Chin, M.D.
Share this article
Share this article
SAN FRANCISCO, April 20, 2021 /PRNewswire/ Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results in a new long-acting interleukin (IL)-31 antibody program (KIND-039) that integrates the company s novel half-life extension technology. Results from the pharmacokinetic study of the molecule demonstrate that the fully caninized, high-affinity antibody has up to a three-fold longer half-life compared to tirnovetmab. This extended half-life is expected to allow for up to three-fold longer interval between dosing. One of the main unmet needs in the canine dermatitis market is reduced dosing frequency and increased convenience. With these exciting results, we believe our new long-acting IL-31 antibody program has the potential to become a best-in-class therapeutic and the treatment of choice in the large and growing dermatitis market, said KindredBi